-
Neurophet teams up with Eisai Korea on AI-based dementia screening
13 Jan 2026 05:22 GMT
… result analysis system.
Eisai Korea will support service … expand service utilization.
Eisai Korea is the Korean … in neuroscience and oncology. Eisai Korea launched Leqembi (lecanemab … hospitals and screening centers,” Eisai Korea CEO Ko Hong-byung said …
-
Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan
12 Jan 2026 17:44 GMT
… , Corporate Headquarters: New York, NY, CEO: David Hung, M.D., … cancer treatment, and Eisai Co., Ltd (Headquarters: Tokyo, CEO: Haruo Naito, … , President, and Chief Executive Officer of Nuvation Bio. "With Eisai's …
-
Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders
31 Dec 2025 13:00 GMT
… from the Company’s Chief Executive Officer.
Dear Shareholders, … assumed the role of Chief Executive Officer. Since that time … Sincerely,
Thomas H. Jensen
Chief Executive Officer
About Stenoparib/2X … which was originally developed by Eisai Co. Ltd. and was …
-
Eisai Presents New Data On The Continued And Expanding Benefit Of LEQEMBI(R) (Lecanemab-Irmb) Maintenance Treatment In Early Alzheimer's Disease At CTAD 2025
07 Dec 2025 10:26 GMT
… (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, … ;Eisai") and Biogen Inc …
-
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer’s Disease at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025
03 Dec 2025 23:10 GMT
… NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen … Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: … Europe, please visit www.eisai.eu and Eisai EMEA LinkedIn.
About …
-
Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025
02 Dec 2025 01:58 GMT
… / -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito) … Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0 … -753-1945
Libby_Holman@eisai.com
*DIAD: Dominantly … through collaborative research between Eisai and University College London. …
-
Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer’s Disease in Japan
28 Nov 2025 00:30 GMT
… NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen … , Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that Eisai has filed …
-
Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status
25 Nov 2025 12:30 GMT
… NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen … , Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that Eisai has completed …
-
Japan – Eisai and Biogen Announce U.S. Availability of LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer’s Disease
09 Oct 2025 14:00 GMT
… Newswire) – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen … Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO … regulative submissions internationally with Eisai and Biogen co- …
-
Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer’s Disease
06 Oct 2025 20:30 GMT
… NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen … Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO … Europe, please visit www.eisai.eu and Eisai EMEA LinkedIn.
About …
About
© 1995-2026